{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:49:20Z","timestamp":1764874160826,"version":"3.37.3"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,21]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Despite substantial evidence that methotrexate (MTX) has inferior efficacy, safety, and tolerability compared to newer systemic therapies, MTX remains one of the most commonly prescribed first-line systemic therapies for psoriatic arthritis worldwide and for psoriasis in some countries. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting in Dublin, Ireland, Drs. William Tillett and Joseph Merola engaged in debate over whether MTX should be the first systemic therapy used in psoriatic disease (PsD). Each presented evidence-based arguments, incorporating multiple data sources, including clinical trials, in support for and against MTX\u2019s status as first-line systemic therapy for PsD. This article summarizes their debate for the broader PsD community.<\/jats:p>","DOI":"10.3899\/jrheum.2024-0317","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:17:42Z","timestamp":1721045862000},"page":"58-60","source":"Crossref","is-referenced-by-count":2,"title":["Debate at the GRAPPA 2023 Annual Meeting: Should Methotrexate Be the First Systemic Therapy in Psoriatic Disease?"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-0557","authenticated-orcid":false,"given":"Arianna J.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"2024120403401877000_51.Suppl_2.58.1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/247553031218a00402","article-title":"History of methotrexate and use in psoriasis","volume":"18a","author":"Luber","year":"2012","journal-title":"Psoriasis Forum"},{"key":"2024120403401877000_51.Suppl_2.58.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"2024120403401877000_51.Suppl_2.58.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200124"},{"key":"2024120403401877000_51.Suppl_2.58.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2024120403401877000_51.Suppl_2.58.5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/art.40872","article-title":"SEAM-PsA: seems like methotrexate works in psoriatic arthritis?","volume":"71","author":"Merola","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024120403401877000_51.Suppl_2.58.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"2024120403401877000_51.Suppl_2.58.7","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial","volume":"4","author":"Mulder","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024120403401877000_51.Suppl_2.58.8","unstructured":"NHS Electronic Drug Tariff . Part VIIIA \u2013 Basic prices of drugs. [Internet. Accessed April 8, 2024.] Available from: www.drugtariff.nhsbsa.nhs.uk\/#\/00553921-DA\/DA00553911\/Part%20VIIIA%20-%20Basic%20Prices%20of%20Drugs"},{"key":"2024120403401877000_51.Suppl_2.58.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2024120403401877000_51.Suppl_2.58.10","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024120403401877000_51.Suppl_2.58.11","doi-asserted-by":"crossref","first-page":"1759720X221092376","DOI":"10.1177\/1759720X221092376","article-title":"Is there still a place for methotrexate in severe psoriatic arthritis?","volume":"14","author":"Felten","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024120403401877000_51.Suppl_2.58.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2024120403401877000_51.Suppl_2.58.13","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00250-3"},{"key":"2024120403401877000_51.Suppl_2.58.14","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s12325-022-02065-w","article-title":"Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis","volume":"39","author":"Leonardi","year":"2022","journal-title":"Adv Ther"},{"key":"2024120403401877000_51.Suppl_2.58.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2546-x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:41:22Z","timestamp":1733312482000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":15,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.3899\/jrheum.2024-0317"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0317","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}